Comparison

HGH Fragment 176-191 vs Cagrilintide

Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research

HGH Fragment 176-191

Also: Frag 176-191, HGH Frag

Clinical Trials

The lipolytic fragment of human growth hormone. Contains the fat-burning portion of HGH without effects on blood sugar or cell proliferation.

Weight LossHuman Trials
Cagrilintide

Also: AM833, NN9838

Clinical Trials

A long-acting amylin analog developed by Novo Nordisk for obesity treatment. Works through a different mechanism than GLP-1 agonists, targeting amylin receptors in the brain to reduce appetite and slow gastric emptying. Shows enhanced weight loss when combined with semaglutide (CagriSema).

Weight LossHuman Trials

Key Comparison Insights

  • Both peptides belong to the Weight Loss category, suggesting similar primary applications.

Detailed Comparison

AttributeHGH Fragment 176-191Cagrilintide
CategoryWeight LossWeight Loss
FDA StatusNot FDA ApprovedNot FDA Approved
Clinical Status
Pre
I
II
III
IV
FDA
Pre
I
II
III
IV
FDA
Mechanism of ActionFragment 176-191 mimics the way natural HGH regulates fat metabolism but without adverse effects on blood sugar or growth. It stimulates lipolysis and inhibits lipogenesis, specifically targeting adipose tissue.Cagrilintide mimics amylin, a hormone co-secreted with insulin from pancreatic beta cells. It activates amylin and calcitonin receptors in the area postrema and nucleus tractus solitarius of the brainstem, enhancing satiety signaling. Unlike GLP-1 agonists, it works through homeostatic and hedonic appetite centers, reducing hunger and promoting earlier meal termination. Also slows gastric emptying to prolong fullness.
Common Dosing
250-500 mcg daily
1-2x daily, fasted
2.4 mg weekly
Once weekly
AdministrationSubcutaneous injection on empty stomachSubcutaneous injection once weekly
Typical Duration8-12 weeksLong-term / chronic use expected
Best Time to TakeBefore bed or morning (fasted)Any consistent time weekly
Possible Side Effects
May vary by individual
  • Generally well-tolerated
  • Injection site reactions
  • Mild headache
  • Nausea
  • Does NOT cause typical HGH side effects
  • +2 more
  • Nausea (common, usually transient)
  • Vomiting
  • Diarrhea
  • Constipation
  • Abdominal pain
  • +6 more
Research SummaryStudies show enhanced fat loss, particularly in abdominal area. Research demonstrates no impact on glucose metabolism or IGF-1 levels. Works synergistically with diet and exercise for body composition improvement.REDEFINE 1 Phase 3 trial showed 11.8% weight loss with cagrilintide monotherapy vs 2.3% placebo over 68 weeks. Combined with semaglutide (CagriSema), average weight loss reached 20.4% vs 3.0% placebo. 60% of CagriSema participants achieved ≥20% weight loss, and 23% lost ≥30%. This represents some of the most significant weight loss results seen with any anti-obesity medication.

Frequently Asked Questions: HGH Fragment 176-191 vs Cagrilintide

What is the difference between HGH Fragment 176-191 and Cagrilintide?

HGH Fragment 176-191 is a weight loss peptide that the lipolytic fragment of human growth hormone. contains the fat-burning portion of hgh without effects on blood sugar or cell proliferation. Cagrilintide is a weight loss peptide that a long-acting amylin analog developed by novo nordisk for obesity treatment. works through a different mechanism than glp-1 agonists, targeting amylin receptors in the brain to reduce appetite and slow gastric emptying. shows enhanced weight loss when combined with semaglutide (cagrisema). The main differences lie in their mechanisms of action and clinical applications.

Which is better, HGH Fragment 176-191 or Cagrilintide?

Neither is universally "better" - the choice depends on your specific goals. HGH Fragment 176-191 is typically used for weight loss purposes, while Cagrilintide is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.

Can HGH Fragment 176-191 and Cagrilintide be used together?

Some peptide protocols combine multiple compounds for synergistic effects. However, using HGH Fragment 176-191 and Cagrilintide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.

Related Comparisons

View Full Peptide Profiles

Educational Information Only

This comparison of HGH Fragment 176-191 and Cagrilintide is for educational purposes only. Neither this comparison nor any information on this site constitutes medical advice. Always consult with qualified healthcare providers before making decisions about peptides or other substances.